Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Novo Nordisk stock faces an FDA delay as Q2 sales grow 7 percent

Earnings report Regulatory approval AI-generated analysis

πŸ“ˆ Novo Nordisk Q2 adjusted sales grew 7 percent at constant exchange rates to reach DKK 78.5 billion.

πŸ’° Adjusted operating profit increased 11 percent to DKK 33.4 billion, though margins compressed to 78.2 percent.

πŸ“‰ Obesity-care sales surged 16 percent in Q2 while international GLP-1 sales grew 13 percent.

⚠️ The FDA extended its review of denecimig due to manufacturing facility remediation work, delaying the U.S. launch to H1 2027.

πŸ”¬ Clinical efficacy and safety data for denecimig remain unaffected by the regulatory delay.

πŸ’Š Novo Nordisk acquired rights to HRS-1596 from Jiangsu Hengrui Pharmaceuticals for up to USD 2.6 billion.

πŸ“… The company expects full-year 2026 adjusted sales growth of 0% to -6% at constant exchange rates.

πŸ—“οΈ Q3 earnings are scheduled for release on November 3, 2026.

Bullish Signals
  • Novo Nordisk achieved a 7 percent increase in Q2 adjusted sales at constant exchange rates, reaching DKK 78.5 billion.
  • Obesity-care sales grew robustly by 16 percent in Q2, demonstrating strong demand for the company's core weight-loss portfolio.
  • International GLP-1 sales expanded by 13 percent in Q2, indicating successful volume growth outside domestic markets.
  • Adjusted operating profit rose 11 percent to DKK 33.4 billion despite margin compression from lower prices and capacity costs.
  • The company secured a strategic acquisition of HRS-1596 rights for up to USD 2.6 billion, diversifying its obesity treatment pipeline.
Risk Factors
  • The FDA extended the review period for denecimig due to remediation work at a manufacturing facility, delaying the U.S. launch to the first half of 2027.
  • Adjusted gross margin declined to 78.2 percent from 82.7 percent in the prior year quarter due to lower realized prices and manufacturing capacity costs.
  • Management forecasts flat-to-negative adjusted sales growth for full-year 2026, ranging from 0% to -6% at constant exchange rates.
Full Analysis
Novo Nordisk reported strong Q2 adjusted sales growth of 7 percent at constant exchange rates, reaching DKK 78.5 billion, driven by a 16 percent increase in obesity-care sales and 13 percent growth in international GLP-1 volumes. Despite this revenue expansion, the company's adjusted gross margin declined to 78.2 percent from 82.7 percent in the prior year quarter due to lower realized prices and increased manufacturing capacity costs. Adjusted operating profit rose 11 percent to DKK 33.4 billion at constant exchange rates, though management maintains a flat-to-negative growth outlook for full-year 2026 ranging from 0% to -6%. The company faces a regulatory delay regarding its denecimig update in the U.S., with the FDA extending its review to address remediation work at a manufacturing facility. This regulatory action does not impact clinical efficacy or safety data and is expected to shift the potential U.S. launch timeline to the first half of 2027. Strategically, Novo Nordisk agreed to acquire rights to HRS-1596, an experimental once-weekly obesity pill from Jiangsu Hengrui Pharmaceuticals, for up to USD 2.6 billion including a USD 300 million upfront payment. The company is preparing for its Q3 earnings release on November 3, 2026, where investors will assess the impact of pricing pressures and manufacturing execution against continued volume expansion in its core weight-loss portfolio.